...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: https://scr.zacks.co...
7
May 04, 2020 10:59AM
5
May 04, 2020 11:02AM

Nice find Fuzzy. Glad to see Zenith getting some attention. At the same time, I no longer see Resverlogix on the list of covered companies for Zacks/SCR. John Vandermosten and Zacks were the most frequent to update their Resverlogix analysis. 

BDAZ

4
May 05, 2020 07:32PM
8
May 06, 2020 08:51AM
2
May 06, 2020 09:35AM
4
May 06, 2020 03:21PM
Share
New Message
Please login to post a reply